Senator Richard Burr’s Statement on Mark-Up of FDA Safety and Innovation Act

Today, U.S. Senator Richard Burr (R-NC) issued the following statement on the Senate Health, Education, Labor and Pensions (HELP) Committee's mark-up of the Food and Drug Administration Safety and Innovation Act:

"I am pleased that many of the key provisions of the Burr-Coburn PATIENTS' FDA Act are included in the manager's package we are considering today, and I am even more pleased that we found a bipartisan path forward to increase transparency and accountability at FDA. These provisions support meaningful congressional oversight that will help ensure timely decisions on behalf of America's patients.

"America's patients deserve access to the latest, most effective life-saving treatments, but red-tape at the FDA is stifling scientific investment and innovation, which is a disservice to medical innovators and can delay patients' access to medical therapies.

"I am also pleased that the Advancing Breakthrough Therapies for Patients Act, a bipartisan bill I introduced with Senators Bennett and Hatch, was also included in today's package. We owe it to patients to provide a clear pathway for expediting the development and review of breakthrough therapies so promising innovation can reach patients as soon as possible.

"I look forward to working with my colleagues to find a workable path forward on bipartisan legislation to secure the pharmaceutical distribution supply chain integrity."